Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 10/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 7/20 | 0.44 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.43 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.43 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2291317 | 0.92 | BCHE (0.43) | MAOBFFAR1FFAR4BCHE | |
| SCHEMBL1539478 | 0.88 | MAPT (0.50) | MAOBFFAR1FFAR4RAB9AALDH1A1 | |
| SCHEMBL2292614 | 0.85 | MAOA (0.47) | MAOBRAB9ABCHE | |
| SCHEMBL28497262 | 0.81 | ALDH1A1 (0.54) | MAOBFFAR1FFAR4RAB9ABCHE | |
| SCHEMBL1539485 | 0.81 | POLB (0.48) | MAOBFFAR1FFAR4SENP8SENP7 | |
| SCHEMBL2290698 | 0.81 | MAOB (0.44) | MAOBFFAR1FFAR4AKR1B1RAB9A | |
| SCHEMBL1200712 | 0.81 | SMN1; SMN2 (0.50) | MAOBRAB9ATHRBALDH1A1 | |
| SCHEMBL2288028 | 0.81 | KMT2A (0.42) | FFAR1FFAR4RAB9AALDH1A1 | |
| SCHEMBL2291416 | 0.81 | L3MBTL1 (0.42) | FFAR1FFAR4RAB9ATHRBALDH1A1 | |
| SCHEMBL2291294 | 0.80 | THRB (0.36) | FFAR1FFAR4RAB9ATHRBBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2149545-B1 | METHOD FOR PRODUCING BENZALDEHYDE COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2016-10-05 | — | — | EP | disclosed |
| US-7994367-B2 | Method for producing benzaldehyde compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-08-09 | — | — | US | disclosed |
| US-20100210879-A1 | METHOD FOR PRODUCING BENZALDEHYDE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-08-19 | — | — | US | disclosed |
| EP-2149545-A1 | METHOD FOR PRODUCING BENZALDEHYDE COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2010-02-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210879-A1 | METHOD FOR PRODUCING BENZALDEHYDE COMPOUND | NQO1, C9, TRPA1 | MAOB 272/4885FFAR1 3643/4885FFAR4 3092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.